TREATMENT OF CD20-POSITIVE B-CELL LYMPHOMA WITH OBITUZUMABThe present disclosure relates to administration speed of obinutuzumab.Michael WENGERMehrdad MOBASHERChin-Yu LIN
1.Armitage J O. Treatment of Non-Hodgkin's Lymphoma[J]. New England Journal of Medicine, 1993...
Reactivation of hepatitis B virus (HBV) after rituximab-containing chemotherapy in patients with B-cell lymphoma has been recognized as a potentially serious complication in HBV immune patients. 关键词: hepatitis B virus reactivation B-cell lymphoma rituximab antibody to hepatitis B core antigen 年份...
套细胞淋巴瘤(MCL)是一种侵袭性 B 细胞恶性肿瘤。尽管过去 20 年中 MCL 的治疗取得了明显进步,但疾病进展和早期复发的患者仍面临诸多临床挑战。新的靶向治疗、免疫治疗和 CD20 抗体维持治疗极大改变了 MCL 患者的临床结局。 奥妥珠单抗...
绝大部分的B淋巴细胞瘤都有CD20的表达,CD20分子易与抗体结合,且结合后不易脱落、不内化,成为治疗B细胞淋巴瘤的理想靶抗原。目前,抗CD20单克隆抗体是治疗B细胞淋巴瘤(B-cell non-Hodgkin’s lymphoma)的重要靶向药(图1) [4]! 图1. 抗CD20单克隆抗体是治疗BCL的重要靶向药 [4]...
Anti-CD20 Monoclonal Antibody (Rituximab) for Therapy of Mediastinal CD20-Positive Large B-Cell Non-Hodgkin Lymphoma with a Local Tumor Extension into the ... Intravenous therapy with the anti-CD20 antibody Rituximab has been recently approved for the treatment of CD20 positive non-Hodgkin's lymph...
8.Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma ...
[5] KATCHI T,LIU D.Diagnosis and treatment of CD20 negative B cell lymphomas[J].Biomark Res,2017(5):5. [6] S HIN-ICHI N,CHIKAO Y,MASAKO K,et al.An unusual case of Epstein-Barr virus-positive large B-cell lymphoma lacking various B-cell markers [J].Diagnostic Pathology,2017,12(...
this is the first report of CD20-positive T-cell lymphoma occurring subsequent to treatment of Hodgkin's disease. The current case affords an opportunity to review the rarely reported expression of CD20 in T-cell neoplasms as well as the relationship between Hodgkin's disease and subsequently occu...
Ofatumumab (OFA, trade name Arzerra) is a fully human CD20-specific antibody that is active against CD20-positive B-cell lymphoma/chronic lymphocytic leukemia cells. In order to further enhance the anticancer effect of OFA, anti-CD20 OFA has been conjugated with highly cytotoxic monomethyl ...